Filing Flows

Filing Flows › AstraZeneca (AZN) › Next earnings date

AstraZeneca (AZN) earnings: missed the estimate

AstraZeneca (AZN) reported on Oct 30, 2026 and missed the EPS estimate: $1.00 against $1.15 (-12.7%). Revenue was $16.2B for Q3 2026, +7% year over year. It beat the EPS estimate in 67% of the quarters on record.

Last result−12.7% vs estimate
Beat rate67%

The last report

AstraZeneca reported revenue of $16.2B for the third quarter 2026 (+7% Y/Y), net earnings $3.1B: Oncology $7.1B, CVRM $2.6B, Farxiga $1.6B, Ultomiris $1.4B. How it makes money → · Every quarter →

AstraZeneca: EPS against the estimate, last 3 reportsAstraZeneca: EPS against the estimate, last 3 reportsEstimateReported$1.27$1.29Apr 26$1.25$1.31Jul 26$1.15$1.00Oct 26
Latest (Oct 26): Estimate $1.15, Reported $1.00.

AstraZeneca's latest quarter

AstraZeneca, Q3 2026: revenue $16.2B (+7% year over year), operating margin 27.1%, net earnings $3.1B, operating cash flow $5.8B. The chart follows the revenue to costs, profit and cash.

Questions

Did AstraZeneca beat earnings?

AstraZeneca (AZN) reported on Oct 30, 2026 and missed the EPS estimate: $1.00 against $1.15 (-12.7%).

When does AZN report earnings?

The next date is not set yet.

Does AstraZeneca usually beat earnings?

It beat the consensus EPS estimate in 67% of the quarters on record.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.